Thesis
Nectin-4 ADC with 43% ORR in platinum-resistant OPSCC enters registrational trial — whether single-arm-style ORR data secures accelerated approval is the make-or-break
CRB-701, a Nectin-4 antibody-drug conjugate targeting platinum-resistant head and neck and cervical cancers, posted a confirmed 42.9% ORR in second-line OPSCC with a discontinuation rate below 3%, prompting FDA alignment on a 250-patient randomized trial using ORR for accelerated approval. The thesis resolves on whether that randomized ORR readout satisfies FDA's accelerated approval bar without a safety or generalizability finding that derails the filing. Burn of $36M per quarter against $118M in cash constrains the runway, and the obesity pivot candidate CRB-913 remains unproven at Phase 1b.
Focus
TEMPO-1 registrational study initiation in 2L OPSCC
September 2026
Bull
A positive outcome is TEMPO-1 enrolling efficiently and generating a confirmed ORR that meets or exceeds the 42.9% signal seen in Phase 1/2, with a durable response profile and manageable safety — this would position Corbus to file for accelerated approval on single-arm-style ORR data with OS follow-up ongoing, representing a clear path to the first approved Nectin-4 ADC in OPSCC and a significant valuation re-rating.
Bear
The most likely failure modes are ORR dilution in a larger, more heterogeneous randomized population relative to the small Phase 1/2 cohort (n=21), or the FDA raising the bar beyond ORR alone and requiring OS maturity before granting accelerated approval — slow enrollment in a relatively narrow platinum-resistant OPSCC population could also delay the readout and compress the runway given the accelerating cash burn.
Unlock the full thesis for CRBP.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.